ACE2 and heart failure: Our earlier study observed a similar trend as a low dose of daunorubicin, mimicking early-stage of heart failure, produced an increase in cardiac ACE2 mRNA levels whilst the higher dose markedly decreased ACE2, suggesting a direct effect of chronic daunorubicin cardiomyopathy (end-stage heart failure) on ACE2 expression [160].